Bristol-Myers Squibb (NYSE:BMY) Shares Acquired by Investors Asset Management of Georgia Inc. GA ADV

Investors Asset Management of Georgia Inc. GA ADV lifted its position in Bristol-Myers Squibb (NYSE:BMY) by 10.1% during the fourth quarter, HoldingsChannel.com reports. The fund owned 8,557 shares of the biopharmaceutical company’s stock after acquiring an additional 785 shares during the period. Investors Asset Management of Georgia Inc. GA ADV’s holdings in Bristol-Myers Squibb were worth $484,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. FDx Advisors Inc. boosted its stake in Bristol-Myers Squibb by 13.8% during the 4th quarter. FDx Advisors Inc. now owns 6,480 shares of the biopharmaceutical company’s stock worth $367,000 after purchasing an additional 784 shares during the last quarter. Lakeside Advisors INC. boosted its position in Bristol-Myers Squibb by 7.4% during the fourth quarter. Lakeside Advisors INC. now owns 4,394 shares of the biopharmaceutical company’s stock worth $249,000 after acquiring an additional 302 shares during the last quarter. Boston Financial Mangement LLC raised its holdings in Bristol-Myers Squibb by 2.1% in the 4th quarter. Boston Financial Mangement LLC now owns 9,505 shares of the biopharmaceutical company’s stock valued at $538,000 after acquiring an additional 200 shares during the last quarter. First Bank & Trust lifted its stake in Bristol-Myers Squibb by 49.2% in the 4th quarter. First Bank & Trust now owns 60,268 shares of the biopharmaceutical company’s stock worth $3,409,000 after purchasing an additional 19,878 shares in the last quarter. Finally, Advyzon Investment Management LLC acquired a new position in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $458,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

BMY has been the subject of several recent research reports. Jefferies Financial Group raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and increased their price target for the company from $63.00 to $70.00 in a report on Monday, December 16th. Morgan Stanley lifted their price target on Bristol-Myers Squibb from $36.00 to $39.00 and gave the stock an “underweight” rating in a report on Tuesday, November 12th. Leerink Partnrs raised shares of Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a report on Tuesday, November 12th. Truist Financial lifted their target price on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. Finally, Bank of America reissued a “neutral” rating and issued a $63.00 price target on shares of Bristol-Myers Squibb in a research note on Tuesday, December 10th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, four have given a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, Bristol-Myers Squibb has a consensus rating of “Hold” and a consensus price target of $57.86.

Insider Activity at Bristol-Myers Squibb

In other news, EVP Samit Hirawat purchased 1,823 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The stock was bought at an average price of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the purchase, the executive vice president now directly owns 63,932 shares of the company’s stock, valued at $3,506,030.88. The trade was a 2.94 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.09% of the stock is currently owned by company insiders.

Bristol-Myers Squibb Price Performance

BMY stock opened at $55.80 on Friday. The company has a market capitalization of $113.23 billion, a PE ratio of -12.62, a P/E/G ratio of 2.02 and a beta of 0.45. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. The business’s fifty day moving average price is $56.99 and its 200 day moving average price is $54.24. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $61.10.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, beating the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. On average, sell-side analysts anticipate that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Bristol-Myers Squibb Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd were paid a $0.62 dividend. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. This represents a $2.48 annualized dividend and a dividend yield of 4.44%. The ex-dividend date of this dividend was Friday, January 3rd. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -56.11%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.